Skip to main content
. 2022 Nov 5:10.1111/febs.16662. Online ahead of print. doi: 10.1111/febs.16662

Table 3.

Summary of recommendations for protein trafficking and post‐translational modifications targeted antivirals. Both antivirals in this section are not authorized for COVID‐19 treatment.

Antiviral Timing of treatment References
Nitazoxanide Not authorized for COVID‐19 treatment [159]
Ivermectin Not authorized for COVID‐19 treatment [160]